• Avoid or wait on Sarepta (SRPT) until its weak results, shrinking revenue stream, and inventory and cost uncertainties are clearer.
• For a longer-term view, monitor the DM1 and FSHD Phase 3 programs and reassess as trial progress and company financials provide more clarity.

Sarepta Therapeutics (SRPT)

• The speaker called Sarepta’s Q3 results “pretty stinky” and said the stock had continued to fall. He described the company as potentially “cooked,” but also said he liked the management team and did not want to reach a conclusion before reviewing more information.
• He said a product or revenue stream referred to in the transcript as “Elevitus” or “Levitas” was shrinking. The product name is unclear in the transcript, so it is difficult to assess this comment more specifically.
• The discussion highlighted uncertainty about Sarepta’s cost of goods sold and noted what the speaker described as $1 billion in inventory on the balance sheet.
• The potential upside discussed was the pipeline, including Phase 3 programs in DM1 and FSHD. The speaker suggested that investors would have to wait for the pipeline to mature.
• He also discussed an existing revenue stream that he said was unlikely to be disrupted by generics, while acknowledging uncertainty about its current margins and economics. The transcript does not clearly identify that revenue stream.

Takeaways

• The discussion is cautious to bearish near term, citing weak results, falling shares, a shrinking revenue source, and uncertainty about costs and inventory.
• The pipeline offers a possible longer-term source of value, but the speaker gave no price target or timeline for success. Investors may want to follow the progress of the DM1 and FSHD Phase 3 programs alongside Sarepta’s financial results.
• The transcript leaves key details unclear—including the product name and current margins—so verify those points against company filings before drawing conclusions.